📇 Rhumatologue · VITRY SUR SEINE · (94) · Libéral

M Mouaffak ISSA

Pourquoi vous devez consulter ce praticien

3 raisons identifiées

Auteur de référence en rhumatologie
32 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
134 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 VITRY SUR SEINE (94)LibéralRPPS 10001579530

✨ Génération du profil synthétique IA en cours…

Lieux de consultation(2)

CABINET DU DR MOUAFFAK ISSA
10 RUE ROSA PARKS, 94400 VITRY SUR SEINE
Activité de soin et de pharmacie
CDS MUNICIPAL DE SANTE MAURICE TENINE
15 R MARCEL ET GEORGETTE SEMBAT, 94500 CHAMPIGNY SUR MARNE
☎ 0148825500Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

Arthritis & rheumatology (Hoboken, N.J.) · 2019

📚 138 citations🎯 RCR 6.39Top 5% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ObjectiveTo assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA).MethodsData were pooled from 9 RA studies. Placebo comparison up to 24 weeks included data from 6 studies. Randomized dose comparison between baricitinib doses of 2 mg and 4 mg used data from 4 studies and from the associated long‐term extension study. The data analysis set designated “All‐bari‐RA” included all baricitinib exposures at any dose.ResultsOverall, 3,492 RA patients received baricitinib (7,860 patient‐years of exposure). No imbalance compared to the placebo group was seen in the incidence of major adverse cardiovascular events (MACE) (incidence rates [IRs] of 0.5 per 100 patient‐years for placebo and 0.8 per 100 patient‐years for 4 mg baricitinib), arterial thrombotic events (ATE) (IRs of 0.5 per 100 patient‐years for placebo and 0.5 per 100 patient‐years for 4 mg baricitinib), or congestive heart failure (CHF) broad term (IRs of 4.3 per 100 patient‐years for placebo and 2.4 per 100 patient‐years for 4 mg baricitinib). Deep vein thrombosis (DVT)/pulmonary embolism (PE) were reported in 0 of 1,070 patients treated with placebo and 6 of 997 patients treated with 4 mg baricitinib during the placebo‐controlled period; these events were serious in 2 of 6 patients, while all 6 had risk factors and 1 patient developed DVT/PE after discontinuation of the study drug. In the 2 mg–4 mg‐extended data analysis set, IRs of DVT/PE were comparable between the doses across event types (IRs of 0.5 per 100 patient‐years in those receiving 2 mg baricitinib and 0.6 per 100 patient‐years in those receiving 4 mg baricitinib). In the All‐bari‐RA data analysis set, the rates were stable over time, with an IR of DVT/PE of 0.5 per 100 patient‐years.ConclusionIn RA clinical trials, no association was found between baricitinib treatment and the incidence of MACE, ATE, or CHF. With regard to incidence of DVT/PE, 6 events occurred in patients treated with 4 mg baricitinib, but no cases of DVT/PE were reported in the placebo group. During longer‐term evaluation, the incidence of DVT/PE was similar between the baricitinib dose groups, with consistent IR values over time, and this was similar to the rates previously reported in patients with RA.

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Annals of the rheumatic diseases · 2022

📚 133 citations🎯 RCR 13.12Top 2% NIH🔓 Open Access📄 PDF gratuit ↗

Infections in baricitinib clinical trials for patients with active rheumatoid arthritis

Annals of the rheumatic diseases · 2020

📚 74 citations🎯 RCR 3.82Top 12% NIH🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

M Mouaffak ISSA

Pourquoi vous devez consulter ce praticien

Lieux de consultation(2)

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (32) — classées par pathologie

JAK inhibiteurs15

Transversal6

csDMARDs3

Épidémiologie & registres2

Revue / méta-analyse2

Sjögren2

Anti-TNF1

Case report / série1

Essai clinique1

Lupus1

Revue générale1

Tendinopathies & SCC1

Partager cette fiche